What is the comparative efficacy of latanoprost (prostaglandin F2alpha analog) versus bimatoprost (prostaglandin F2alpha analog) for promoting eyelash growth?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bimatoprost vs Latanoprost for Eyelash Growth

Bimatoprost is more effective than latanoprost for promoting eyelash growth, with stronger evidence supporting its use for this specific purpose. 1, 2

Comparative Efficacy

Bimatoprost

  • FDA-approved specifically for eyelash hypotrichosis (inadequate eyelashes) as Latisse® (0.03% solution) 3, 4
  • In a multicenter, randomized, double-masked, vehicle-controlled study, 78.1% of subjects using bimatoprost demonstrated at least a 1-grade increase in eyelash prominence after 16 weeks 2
  • Produces measurable increases in:
    • Eyelash length
    • Thickness
    • Darkness
    • Number of eyelashes 2, 5

Latanoprost

  • Not FDA-approved specifically for eyelash growth
  • Shows more modest effects on eyelash growth compared to bimatoprost
  • In a quantitative analysis, latanoprost increased eyelash length from 5.8mm to 6.6mm (0.8mm increase) after 10 weeks of treatment 6
  • Less consistent results for cosmetic eyelash enhancement 7

Mechanism of Action

Both medications are prostaglandin F2α analogs that work by:

  • Stimulating resting hair follicles (telogen phase) to enter the growth phase (anagen phase)
  • Prolonging the anagen phase, resulting in longer eyelashes 4
  • Increasing melanin content in eyelashes, making them appear darker 8

Safety Profile

Bimatoprost

  • Most common side effect is conjunctival hyperemia (45% of users) 3
  • Other potential side effects include:
    • Eyelid skin darkening (may be reversible)
    • Iris pigmentation changes (likely permanent)
    • Rare cases of anterior uveitis 7, 3

Latanoprost

  • Generally similar side effect profile to bimatoprost but with:
    • Lower incidence of conjunctival hyperemia
    • Similar risk of eyelid skin darkening and iris pigmentation changes 8
    • Better overall tolerability profile 1

Application Method

For optimal eyelash growth:

  • Apply once daily to the upper eyelid margin at the base of the eyelashes
  • Remove contact lenses before application (can be reinserted 15 minutes after with latanoprost) 8
  • Consistent application is necessary for continued results
  • Effects are reversible upon discontinuation for eyelash characteristics, but iris color changes may be permanent 3, 8

Important Considerations

  • Both medications were originally developed for glaucoma treatment and lower intraocular pressure 1
  • Monitor for intraocular pressure changes, especially in patients with risk factors for glaucoma 7
  • Avoid allowing the applicator tip to contact the eye to prevent contamination 8
  • Effects on eyelash growth are typically noticeable within 8-16 weeks of consistent use 2, 5
  • Discontinuation leads to gradual return to baseline eyelash characteristics within weeks to months 8

Conclusion

For patients specifically seeking eyelash enhancement, bimatoprost 0.03% provides superior results compared to latanoprost, with more substantial increases in eyelash length, thickness, and darkness. However, patients should be informed about potential side effects, particularly the risk of permanent iris color change and periorbital skin darkening.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Bimatoprost in the treatment of eyelash hypotrichosis.

Clinical ophthalmology (Auckland, N.Z.), 2010

Research

Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2010

Research

Quantitative analysis of eyelash lengthening following topical latanoprost therapy.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2002

Guideline

Eyelash Health Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.